SC Japan Oncology RWDby Sumitomo Corporation
April 2026 - Japan Oncology RWE

Japan Oncology RWD

A portal for Japan clinical RWD and clinico‑genomic evidence.

Request Feasibility Query Explore Data Assets
80,000+
Patients in EMR catalog
NTT Cyber Oncology
23,000+
Clinico-genomic cases
SCRUM Japan VAPORCONE
270
Participating sites
National network
20+
Tumor types covered
Solid + hematologic
Vision

A Japan cancer data hub for global R&D and AI

Sumitomo connects hospital networks, research platforms, and technology partners through one route.

Our vision

Make Japan oncology evidence easier to scope and use.

This portal turns the data hub vision into a practical entry point for pharma, biotech, and AI teams.

Feasibility JRA coordination RWE analytics AI-ready research data
Japan network Major cancer hospitals
Hospital registry EMR / labs Biomarkers / CGP
Sumitomo role Japan oncology data hub

Coordinate feasibility, partner access, governance, and research execution.

Global demand Pharma - Biotech - AI
Drug discovery Clinical development Regulatory evidence Model training
Research needs + technology
Data needs + clinical trial planning
Data architecture

Two data sources, one oncology insight layer

EMR RWD and clinico-genomics stay distinct, but discoverable through one entry point.

Clinical Research Database SCRUM-Japan VAPORCONE

Regulatory-grade cancer genome database from NCC East and 270+ SCRUM facilities.
Integrated insight layer Actionable Japan oncology evidence
Cohort sizing Biomarker strategy Endpoint benchmarks External control planning
RWD Database J-CONNECT Cyber Oncology

Cancer registry integrating treatment, lab, biomarker, and EMR-supplemented data.
Explore Data Assets
Why Japan matters

Compelling oncology market, complex data ecosystem

Japan is central to global oncology, but its clinical data ecosystem is hard to navigate.

01

3rd-largest pharma market

Core to global oncology launch and regulatory strategy.

02

Distinct tumor biology

Higher EGFR rates in NSCLC and distinct GI cancer profiles.

03

Different treatment patterns

Sequencing, titration, and standard of care differ by market.

04

PMDA accepts RWE

SCRUM-Japan data set a Japan external-control precedent.

Why Sumitomo

Regulatory-grade access through one contact

Integrated data access

Relationships across clinical RWD and clinico-genomic platforms support coordinated feasibility.

Regulatory-grade quality

Prospective, JRA-governed data collection supports research-grade use.

Coordinated engagement

One route for KOL access, study setup, data delivery, and follow-on planning.

About Sumitomo Corporation

Global presence, anchored in Japan

1919Established
83,430Employees, consolidated
508Subsidiaries & associated companies
31 yearsFortune Global 500 listed
CompanySUMITOMO CORPORATION
RepresentativeShingo Ueno, President & CEO
Paid-in Capital221.6 billion yen
OfficesJapan: 21 - Overseas: 104
Head OfficeOTEMACHI PLACE EAST TOWER, 3-2 Otemachi 2-Chome, Chiyoda-ku, Tokyo 100-8601

As of September 30, 2025. Source: Sumitomo Corporation corporate fact sheet.

Ready to scope your Japan oncology question?

Run an initial feasibility check before a Joint Research Agreement.

Request Feasibility Query